Format

Send to

Choose Destination
BMC Biochem. 2007 Nov 22;8 Suppl 1:S14.

Patented small molecule inhibitors in the ubiquitin proteasome system.

Author information

1
Hybrigenics SA, 3-5 Impasse Reille, 75014 Paris, France. pguedat@hybrigenics.com

Abstract

Deregulation of the ubiquitin proteasome system (UPS) has been implicated in the pathogenesis of many human diseases, including cancer and neurodegenerative disorders. The recent approval of the proteasome inhibitor Velcade(R) (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma establishes this system as a valid target for cancer treatment. We review here new patented proteasome inhibitors and patented small molecule inhibitors targeting more specific UPS components, such as E3 ubiquitin ligases and deubiquitylating enzymes. Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).

PMID:
18047738
PMCID:
PMC2106365
DOI:
10.1186/1471-2091-8-S1-S14
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center